Caricamento...
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs). It has demonstrated comparable efficacy to...
Salvato in:
| Pubblicato in: | Psoriasis (Auckl) |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Dove
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6717840/ https://ncbi.nlm.nih.gov/pubmed/31696051 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PTT.S161453 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|